



(51) International Patent Classification:

A61K 35/407 (2015.01) *C12Q 1/00* (2006.01)
C12N 5/00 (2006.01) *G01N 33/50* (2006.01)
C12N 15/01 (2006.01)

(21) International Application Number:

PCT/US2017/059845

(22) International Filing Date:

03 November 2017 (03.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/417,371 04 November 2016 (04.11.2016) US
62/517,414 09 June 2017 (09.06.2017) US

(71) Applicant: **CHILDREN'S HOSPITAL MEDICAL CENTER** [US/US]; 3333 Burnett Avenue, Cincinnati, OH 45229 (US).

(72) Inventors: **TAKEBE, Takanori**; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). **SHINOZAWA, Tadahiro**; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). **KIMURA, Masaki**; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). **KOIKE, Hiroyuki**; c/o 3333 Burnett Avenue, Cincinnati, Ohio 45229 (US).

(74) Agent: **TEPE, Nicole, M.** et al.; Frost Brown Todd LLC, 3300 Great American Tower, 301 East Fourth Street, Cincinnati, OH 45202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME




FIG. 1

(57) Abstract: Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and/or drug induced liver injury (DILI), and/or drug toxicity. The disclosed liver organoids may also be used to treat an individual having liver damage, or for identifying a preferred therapeutic agent.

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*